Srikala Sridhar, MD; University of Toronto, Princess Margaret Cancer Centre; 5Live; #ASCOGU21
COVID-19: Impact on Caring for Your Patients With Genitourinary Cancers_ Episode 2
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
Neal Shore, MD, FACS; Carolina Urologic Research Center 5Live #ASCO20
Key Insights on HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer.
Elizabeth R. Plimack, MD; Fox Chase Cancer Center 5Live #ASCO20
Key insights on Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.
Episode 1 - COVID-19: Impact on Caring for Your Patients With Genitourinary Cancers
Neal Shore, MD, FACS
Presentation on Recent Advances in the Treatment of mHSPC and nmCRPC: New Options to Delay Progression to mCRPC from ASCO 2019 satellite symposium.
Charles Ryan, MD
Presentation on Optimizing Outcomes: Management of Cardiovascular Risk Factors from ASCO 2019 satellite symposium.
Daniel Petrylak, MD
Presentation on Biomarker-Directed Therapy in Prostate Cancer from ASCO 2019 satellite symposium.
Charles Ryan, MD
Presentation on New Agents and New Targets for the Treatment of mCRPC from ASCO 2019 satellite symposium.
Daniel Petrylak, MD, Karim Fizazi, MD, PhD #ASCO GU2019
Podium to Practice: Current and Future Treatment Options in Prostate Cancer - Impact of Metastases and Hormone Sensitivity presented at the ASCO GU 2019 Conference.